|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | BLOOD |  |  |  | LUNG |  | Pt for SORT |  |
|  |  | HC  (n=15) | IPF  (n=14) | IPAH  (n=10) | PH (non IPAH)a  (n=5) | Control lungb  (n=9) | IPF lung  (n=8) | HC  (n=11) | PFc  (n=11) |
| General | |  | | --- | | age (years) | | male/female (n)(% male) | |  | | 43±10  6/9 (40) | 69±7  11/3 (79) | 48±17  1/10 (10) | 51±10  2/3 (40) | 61±6  5/4 (56) | 63±2  4/7 (36) | 33±6  4/7 (36) | 69±8  3/8 (27) |
| Functional | |  | | --- | | FVC (% predicted | | TLCO (% predicted)  FEV1 (% predicted)  PH secondary to PF yes/no/nd (n)d  Mean PAP (mmHg)  RAP (mmHg)  Cardiac index (L/min/m2)  SvO2 (%)  NYHA-class 2/3 (n)   |  | | --- | |  | | |  | 66±16  37±14  1/0/9 | 55±14  12±6  2.1±0,9  62±7  3/7 | 44±11  8±1  2.9±0,8  67±7  2/3 | 105±17  80±21  105±15 | 50±11  35±8  56±12  3/4/1 |  | 68±18  35±8  3/6/2 |
| medication | Steroids  Pirfenidone  Nintedanib  No treatment  PDE5i  PDE5i + ERA  PDE5i +ERA + Pros-A (n) |  | 2  4  1  7  0  0  0 | 0  0  0  0  2  6  2 | 0  0  0  0  1  3  1 | 0  0  0  0  0  0  0 | 3  0  2  4  0  0  0 |  | 3  5  0  3  0  0  0 |